GALT
Galectin Therapeutics Inc.
$3.68
+3.08%
2026-08-21
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Key Fundamentals
Forward P/E
-2.05
EPS (TTM)
$-0.43
Profit Margin
0.0%
Beta
0.35
Market Cap
$346.9M
Avg Volume (10D)
421K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.55
60D Low
$2.26
Avg Volume
658K
Latest Close
$3.68
Get breakout alerts for GALT
Sign up for Breakout Scanner to receive daily notifications when GALT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Galectin Therapeutics Inc. (GALT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GALT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GALT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.